Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
NCT06700603
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
Sponsor
Rui-hua Xu, MD, PhD